메뉴 건너뛰기




Volumn 65, Issue 4, 2016, Pages 672-682

Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HISTONE H3; HISTONE METHYLTRANSFERASE; INTERFERON STIMULATED GENE; INTERLEUKIN 8; NUCLEIC ACID BINDING PROTEIN; PEGINTERFERON ALPHA; RIBAVIRIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; G9A PROTEIN, MOUSE; HISTONE LYSINE METHYLTRANSFERASE; MESSENGER RNA;

EID: 84932625135     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-309011     Document Type: Article
Times cited : (15)

References (55)
  • 1
    • 84867253160 scopus 로고    scopus 로고
    • The application and mechanism of action of ribavirin in therapy of hepatitis C
    • Thomas E, Ghany MG, Liang TJ. The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir Chem Chemother 2013;23:1-12.
    • (2013) Antivir Chem Chemother , vol.23 , pp. 1-12
    • Thomas, E.1    Ghany, M.G.2    Liang, T.J.3
  • 2
    • 82955163230 scopus 로고    scopus 로고
    • Ribavirin for the treatment of chronic hepatitis C virus infection: A review of the proposed mechanisms of action
    • Paeshuyse J, Dallmeier K, Neyts J. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Curr Opin Virol 2011;1:590-8.
    • (2011) Curr Opin Virol , vol.1 , pp. 590-598
    • Paeshuyse, J.1    Dallmeier, K.2    Neyts, J.3
  • 3
    • 1542377471 scopus 로고    scopus 로고
    • Antiviral action of ribavirin in chronic hepatitis C
    • Pawlotsky J-M, Dahari H, Neumann AU, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004;126:703-14.
    • (2004) Gastroenterology , vol.126 , pp. 703-714
    • Pawlotsky, J.-M.1    Dahari, H.2    Neumann, A.U.3
  • 4
    • 0038820380 scopus 로고    scopus 로고
    • Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin
    • Layden-Almer JE, Ribeiro RM, Wiley T, et al. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatol Baltim Md 2003;37:1343-50.
    • (2003) Hepatol Baltim Md , vol.37 , pp. 1343-1350
    • Layden-Almer, J.E.1    Ribeiro, R.M.2    Wiley, T.3
  • 5
    • 84878169408 scopus 로고    scopus 로고
    • Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients
    • Dietz J, Schelhorn S-E, Fitting D, et al. Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. J Virol 2013;87:6172-81.
    • (2013) J Virol , vol.87 , pp. 6172-6181
    • Dietz, J.1    Schelhorn, S.-E.2    Fitting, D.3
  • 6
    • 0035076685 scopus 로고    scopus 로고
    • Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy
    • Querenghi F, Yu Q, Billaud G, et al. Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy. J Viral Hepat 2001;8:120-31.
    • (2001) J Viral Hepat , vol.8 , pp. 120-131
    • Querenghi, F.1    Yu, Q.2    Billaud, G.3
  • 7
    • 34247552260 scopus 로고    scopus 로고
    • Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy
    • Lutchman G, Danehower S, Song B-C, et al. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 2007;132:1757-66.
    • (2007) Gastroenterology , vol.132 , pp. 1757-1766
    • Lutchman, G.1    Danehower, S.2    Song, B.-C.3
  • 8
    • 84908174040 scopus 로고    scopus 로고
    • Effects of ribavirin monotherapy on the viral population in patients with chronic hepatitis C genotype 1: Direct sequencing and pyrosequencing of the HCV regions
    • Quiles-Pérez R, Muñoz-de-Rueda P, Maldonado AM-L, et al. Effects of ribavirin monotherapy on the viral population in patients with chronic hepatitis C genotype 1: direct sequencing and pyrosequencing of the HCV regions. J Med Virol 2014;86:1886-97.
    • (2014) J Med Virol , vol.86 , pp. 1886-1897
    • Quiles-Pérez, R.1    Muñoz-De-Rueda, P.2    Maldonado, A.M.-L.3
  • 9
    • 34447248532 scopus 로고    scopus 로고
    • Analysis of ribavirin mutagenicity in human hepatitis C virus infection
    • Chevaliez S, Brillet R, Lázaro E, et al. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J Virol 2007;81:7732-41.
    • (2007) J Virol , vol.81 , pp. 7732-7741
    • Chevaliez, S.1    Brillet, R.2    Lázaro, E.3
  • 10
    • 0028825313 scopus 로고
    • Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
    • Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:897-903.
    • (1995) Ann Intern Med , vol.123 , pp. 897-903
    • Di Bisceglie, A.M.1    Conjeevaram, H.S.2    Fried, M.W.3
  • 11
    • 10344259671 scopus 로고    scopus 로고
    • Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study
    • Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996;25:591-8.
    • (1996) J Hepatol , vol.25 , pp. 591-598
    • Dusheiko, G.1    Main, J.2    Thomas, H.3
  • 12
    • 0030227143 scopus 로고    scopus 로고
    • Prolonged therapy of chronic hepatitis C with ribavirin
    • Hoofnagle JH, Lau D, Conjeevaram H, et al. Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepat 1996;3:247-52.
    • (1996) J Viral Hepat , vol.3 , pp. 247-252
    • Hoofnagle, J.H.1    Lau, D.2    Conjeevaram, H.3
  • 13
    • 0031831349 scopus 로고    scopus 로고
    • Ribavirin monotherapy in patients with chronic hepatitis C: A retrospective study of 95 patients
    • Zoulim F, Haem J, Ahmed SS, et al. Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. J Viral Hepat 1998;5:193-8.
    • (1998) J Viral Hepat , vol.5 , pp. 193-198
    • Zoulim, F.1    Haem, J.2    Ahmed, S.S.3
  • 14
    • 84860322902 scopus 로고    scopus 로고
    • New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives
    • Welsch C, Jesudian A, Zeuzem S, et al. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 2012;61(Suppl 1): i36-46.
    • (2012) Gut , vol.61 , pp. i36-46
    • Welsch, C.1    Jesudian, A.2    Zeuzem, S.3
  • 15
    • 84871814966 scopus 로고    scopus 로고
    • Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C
    • Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34-44.
    • (2013) N Engl J Med , vol.368 , pp. 34-44
    • Gane, E.J.1    Stedman, C.A.2    Hyland, R.H.3
  • 16
    • 84899068302 scopus 로고    scopus 로고
    • Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin
    • Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-603.
    • (2014) N Engl J Med , vol.370 , pp. 1594-1603
    • Feld, J.J.1    Kowdley, K.V.2    Coakley, E.3
  • 17
    • 84901036125 scopus 로고    scopus 로고
    • ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis
    • Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-82.
    • (2014) N Engl J Med , vol.370 , pp. 1973-1982
    • Poordad, F.1    Hezode, C.2    Trinh, R.3
  • 18
    • 84925351743 scopus 로고    scopus 로고
    • High efficacy of treatment with Sofosbuvir+ GS-5816+/-Ribavirin for 12 weeks in treatment experienced patients with genotype 1 or 3 HCV Infection
    • Pianko S, Flamm S, Shiffman M, et al. High efficacy of treatment with Sofosbuvir+ GS-5816+/-Ribavirin for 12 weeks in treatment experienced patients with genotype 1 or 3 HCV Infection. Hepatology 2014;60:297A-8A.
    • (2014) Hepatology , vol.60 , pp. 297A-298A
    • Pianko, S.1    Flamm, S.2    Shiffman, M.3
  • 19
    • 84920990853 scopus 로고    scopus 로고
    • Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: Preliminary results of a prospective, multicenter study
    • Flamm S, Everson G, Charlton M, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Hepatology 2014;60:320A-1A.
    • (2014) Hepatology , vol.60 , pp. 320A-3201A
    • Flamm, S.1    Everson, G.2    Charlton, M.3
  • 20
    • 36348960622 scopus 로고    scopus 로고
    • Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response
    • Feld JJ, Nanda S, Huang Y, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatol Baltim Md 2007;46:1548-63.
    • (2007) Hepatol Baltim Md , vol.46 , pp. 1548-1563
    • Feld, J.J.1    Nanda, S.2    Huang, Y.3
  • 21
    • 81155131454 scopus 로고    scopus 로고
    • Ribavirin enhances IFN-α signalling and MxA expression: A novel immune modulation mechanism during treatment of HCV
    • Stevenson NJ, Murphy AG, Bourke NM, et al. Ribavirin enhances IFN-α signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV. PloS ONE 2011;6:e27866.
    • (2011) PloS ONE , vol.6
    • Stevenson, N.J.1    Murphy, A.G.2    Bourke, N.M.3
  • 22
    • 78751545582 scopus 로고    scopus 로고
    • Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models
    • Thomas E, Feld JJ, Li Q, et al. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatol Baltim Md 2011;53:32-41.
    • (2011) Hepatol Baltim Md , vol.53 , pp. 32-41
    • Thomas, E.1    Feld, J.J.2    Li, Q.3
  • 23
    • 84863251369 scopus 로고    scopus 로고
    • Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8
    • Tokumoto Y, Hiasa Y, Uesugi K, et al. Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8. J Infect Dis 2012;205:1121-30.
    • (2012) J Infect Dis , vol.205 , pp. 1121-1130
    • Tokumoto, Y.1    Hiasa, Y.2    Uesugi, K.3
  • 24
    • 84889635179 scopus 로고    scopus 로고
    • Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C
    • Rotman Y, Noureddin M, Feld JJ, et al. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut 2014;63:161-9.
    • (2014) Gut , vol.63 , pp. 161-169
    • Rotman, Y.1    Noureddin, M.2    Feld, J.J.3
  • 25
    • 41149156316 scopus 로고    scopus 로고
    • Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C
    • Asselah T, Bieche I, Narguet S, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008;57:516-24.
    • (2008) Gut , vol.57 , pp. 516-524
    • Asselah, T.1    Bieche, I.2    Narguet, S.3
  • 26
    • 19044361835 scopus 로고    scopus 로고
    • Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection
    • Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005;128:1437-44.
    • (2005) Gastroenterology , vol.128 , pp. 1437-1444
    • Chen, L.1    Borozan, I.2    Feld, J.3
  • 28
    • 50249171227 scopus 로고    scopus 로고
    • Neutral red uptake assay for the estimation of cell viability/cytotoxicity
    • Repetto G, del Peso A, Zurita JL. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc 2008;3:1125-31.
    • (2008) Nat Protoc , vol.3 , pp. 1125-1131
    • Repetto, G.1    Del Peso, A.2    Zurita, J.L.3
  • 29
    • 79957999601 scopus 로고    scopus 로고
    • Chromatin dynamics of gene activation and repression in response to interferon alpha (IFN(alpha)) reveal new roles for phosphorylated and unphosphorylated forms of the transcription factor STAT2
    • Testoni B, Völlenkle C, Guerrieri F, et al. Chromatin dynamics of gene activation and repression in response to interferon alpha (IFN(alpha)) reveal new roles for phosphorylated and unphosphorylated forms of the transcription factor STAT2. J Biol Chem 2011;286:20217-27.
    • (2011) J Biol Chem , vol.286 , pp. 20217-20227
    • Testoni, B.1    Völlenkle, C.2    Guerrieri, F.3
  • 30
    • 44949138461 scopus 로고    scopus 로고
    • A rapid micro chromatin immunoprecipitation assay (microChIP)
    • Dahl JA, Collas P. A rapid micro chromatin immunoprecipitation assay (microChIP). Nat Protoc 2008;3:1032-45.
    • (2008) Nat Protoc , vol.3 , pp. 1032-1045
    • Dahl, J.A.1    Collas, P.2
  • 31
    • 77953893773 scopus 로고    scopus 로고
    • Ribavirin improves early responses to peginterferon through improved interferon signaling
    • Feld JJ, Lutchman GA, Heller T, et al. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 2010;139:154-62.e4.
    • (2010) Gastroenterology , vol.139 , pp. 154-154e4
    • Feld, J.J.1    Lutchman, G.A.2    Heller, T.3
  • 32
    • 0038032916 scopus 로고    scopus 로고
    • Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells
    • Zhang Y, Jamaluddin M, Wang S, et al. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J Virol 2003;77:5933-47.
    • (2003) J Virol , vol.77 , pp. 5933-5947
    • Zhang, Y.1    Jamaluddin, M.2    Wang, S.3
  • 33
    • 78049375674 scopus 로고    scopus 로고
    • General review on in vitro hepatocyte models and their applications
    • Guguen-Guillouzo C, Guillouzo A. General review on in vitro hepatocyte models and their applications. Methods Mol Biol Clifton NJ 2010;640:1-40.
    • (2010) Methods Mol Biol Clifton NJ , vol.640 , pp. 1-40
    • Guguen-Guillouzo, C.1    Guillouzo, A.2
  • 34
    • 84884981804 scopus 로고    scopus 로고
    • Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin
    • Mori K, Hiraoka O, Ikeda M, et al. Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin. Hepatol Baltim Md 2013;58:1236-44.
    • (2013) Hepatol Baltim Md , vol.58 , pp. 1236-1244
    • Mori, K.1    Hiraoka, O.2    Ikeda, M.3
  • 35
    • 34249299791 scopus 로고    scopus 로고
    • The complex language of chromatin regulation during transcription
    • Berger SL. The complex language of chromatin regulation during transcription. Nature 2007;447:407-12.
    • (2007) Nature , vol.447 , pp. 407-412
    • Berger, S.L.1
  • 36
    • 79960913181 scopus 로고    scopus 로고
    • Genome-wide integration on transcription factors, histone acetylation and gene expression reveals genes co-regulated by histone modification patterns
    • Natsume-Kitatani Y, Shiga M, Mamitsuka H. Genome-wide integration on transcription factors, histone acetylation and gene expression reveals genes co-regulated by histone modification patterns. PloS ONE 2011;6:e22281.
    • (2011) PloS ONE , vol.6
    • Natsume-Kitatani, Y.1    Shiga, M.2    Mamitsuka, H.3
  • 37
    • 33846783261 scopus 로고    scopus 로고
    • Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase
    • Kubicek S, O'Sullivan RJ, August EM, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 2007;25:473-81.
    • (2007) Mol Cell , vol.25 , pp. 473-481
    • Kubicek, S.1    O'Sullivan, R.J.2    August, E.M.3
  • 38
    • 84861722003 scopus 로고    scopus 로고
    • Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response
    • Fang TC, Schaefer U, Mecklenbrauker I, et al. Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response. J Exp Med 2012;209:661-9.
    • (2012) J Exp Med , vol.209 , pp. 661-669
    • Fang, T.C.1    Schaefer, U.2    Mecklenbrauker, I.3
  • 39
    • 84881087434 scopus 로고    scopus 로고
    • Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus
    • Helle F, Brochot E, Fournier C, et al. Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus. PloS ONE 2013;8:e70809.
    • (2013) PloS ONE , vol.8
    • Helle, F.1    Brochot, E.2    Fournier, C.3
  • 40
    • 84870567022 scopus 로고    scopus 로고
    • IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection
    • Park H, Serti E, Eke O, et al. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatol Baltim Md 2012;56:2060-70.
    • (2012) Hepatol Baltim Md , vol.56 , pp. 2060-2070
    • Park, H.1    Serti, E.2    Eke, O.3
  • 41
    • 78049401342 scopus 로고    scopus 로고
    • The HepaRG cell line: Biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies
    • Marion M-J, Hantz O, Durantel D. The HepaRG cell line: biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies. Methods Mol Biol Clifton NJ 2010;640:261-72.
    • (2010) Methods Mol Biol Clifton NJ , vol.640 , pp. 261-272
    • Marion, M.-J.1    Hantz, O.2    Durantel, D.3
  • 42
    • 79952305174 scopus 로고    scopus 로고
    • Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C
    • Dill MT, Duong FHT, Vogt JE, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011;140:1021-31.
    • (2011) Gastroenterology , vol.140 , pp. 1021-1031
    • Dill, M.T.1    Duong, F.H.T.2    Vogt, J.E.3
  • 43
    • 84896480771 scopus 로고    scopus 로고
    • Ribavirin for chronic hepatitis e virus infection in transplant recipients
    • Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 2014;370:1111-20.
    • (2014) N Engl J Med , vol.370 , pp. 1111-1120
    • Kamar, N.1    Izopet, J.2    Tripon, S.3
  • 44
    • 84892740572 scopus 로고    scopus 로고
    • Respiratory syncytial virus disease: Prevention and treatment
    • Chu HY, Englund JA. Respiratory syncytial virus disease: prevention and treatment. Curr Top Microbiol Immunol 2013;372:235-58.
    • (2013) Curr Top Microbiol Immunol , vol.372 , pp. 235-258
    • Chu, H.Y.1    Englund, J.A.2
  • 45
    • 84880056374 scopus 로고    scopus 로고
    • Intervention strategies for emerging viruses: Use of antivirals
    • Debing Y, Jochmans D, Neyts J. Intervention strategies for emerging viruses: use of antivirals. Curr Opin Virol 2013;3:217-24.
    • (2013) Curr Opin Virol , vol.3 , pp. 217-224
    • Debing, Y.1    Jochmans, D.2    Neyts, J.3
  • 46
    • 0015523596 scopus 로고
    • Broad-spectrum Antiviral Activity of Virazole: 1-beta-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide
    • Sidwell RW, Huffman JH, Khare GP, et al. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide. Science 1972;177:705-6.
    • (1972) Science , vol.177 , pp. 705-706
    • Sidwell, R.W.1    Huffman, J.H.2    Khare, G.P.3
  • 47
    • 84865791569 scopus 로고    scopus 로고
    • Ribavirin therapy for hepatitis e virus-induced acute on chronic liver failure: A preliminary report
    • Goyal R, Kumar A, Panda SK, et al. Ribavirin therapy for hepatitis E virus-induced acute on chronic liver failure: a preliminary report. Antivir Ther 2012;17:1091-6.
    • (2012) Antivir Ther , vol.17 , pp. 1091-1096
    • Goyal, R.1    Kumar, A.2    Panda, S.K.3
  • 48
    • 84876093975 scopus 로고    scopus 로고
    • Ribavirin treatment of acute and chronic hepatitis E: A single-centre experience
    • Pischke S, Hardtke S, Bode U, et al. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver Int Off J Int Assoc Study Liver 2013;33:722-6.
    • (2013) Liver Int off J Int Assoc Study Liver , vol.33 , pp. 722-726
    • Pischke, S.1    Hardtke, S.2    Bode, U.3
  • 49
    • 0032896077 scopus 로고    scopus 로고
    • Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C
    • McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999;19(Suppl 1):57-65.
    • (1999) Semin Liver Dis , vol.19 , pp. 57-65
    • McHutchison, J.G.1    Poynard, T.2
  • 50
    • 0037179698 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    • Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
    • (2002) N Engl J Med , vol.347 , pp. 975-982
    • Fried, M.W.1    Shiffman, M.L.2    Reddy, K.R.3
  • 51
    • 84907525692 scopus 로고    scopus 로고
    • Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients decompensated genotype-1 patients and genotype-1 patients with prior sofosbuvir treatment experience
    • Gane EJ, Hyland RH, An D, et al. Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience. J Hepatol 2014;60:S3-4.
    • (2014) J Hepatol , vol.60 , pp. S3-4
    • Gane, E.J.1    Hyland, R.H.2    An, D.3
  • 52
    • 84905492815 scopus 로고    scopus 로고
    • Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome
    • Meissner EG, Wu D, Osinusi A, et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 2014;124:3352-63.
    • (2014) J Clin Invest , vol.124 , pp. 3352-3363
    • Meissner, E.G.1    Wu, D.2    Osinusi, A.3
  • 53
    • 0035811016 scopus 로고    scopus 로고
    • RNA virus error catastrophe: Direct molecular test by using ribavirin
    • Crotty S, Cameron CE, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA 2001;98:6895-900.
    • (2001) Proc Natl Acad Sci USA , vol.98 , pp. 6895-6900
    • Crotty, S.1    Cameron, C.E.2    Andino, R.3
  • 54
    • 0032428770 scopus 로고    scopus 로고
    • Respiratory syncytial virus (RSV) disease and prospects for its control
    • Wyde PR. Respiratory syncytial virus (RSV) disease and prospects for its control. Antiviral Res 1998;39:63-79.
    • (1998) Antiviral Res , vol.39 , pp. 63-79
    • Wyde, P.R.1
  • 55
    • 84874107832 scopus 로고    scopus 로고
    • Perspectives and challenges of interferon-free therapy for chronic hepatitis C
    • Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013;58:583-92.
    • (2013) J Hepatol , vol.58 , pp. 583-592
    • Lange, C.M.1    Zeuzem, S.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.